WEREWOLF THERAPEUTICS INC. - COMMON STOCK

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

11 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

04 Mar 2025 08:00:01 By Nasdaq GlobeNewswire

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

24 Feb 2025 07:30:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

13 Jan 2025 08:00:01 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

20 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

07 Nov 2024 09:02:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

07 Nov 2024 09:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases

31 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

04 Oct 2024 09:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

03 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

08 Aug 2024 07:05:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

25 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

01 Jun 2024 08:59:59 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

30 May 2024 08:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

23 May 2024 17:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

03 May 2024 07:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 Apr 2024 10:05:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

23 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

05 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

04 Apr 2024 16:30:00 By Nasdaq GlobeNewswire